Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 777607

Next Previous
Drug Profile

BMS 777607

Alternative Names: ASLAN-002; BMS-777607; BMS-797669

Latest Information Update: 15 Sep 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ASLAN Pharmaceuticals; Bristol-Myers Squibb; Huntsman Cancer Institute
  • Class Aminopyridines; Antineoplastics; Dihydropyridines; Pyridones; Small molecules
  • Mechanism of Action Proto-oncogene protein c-met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Gastric cancer; Head and neck cancer; Osteoporosis; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 15 Sep 2020 Discontinued - Phase-I for Osteoporosis in USA (PO) (Bristol-Myers Squibb pipeline, September 2020) (ASLAN Pharmaceuticals, September 2020)
  • 15 Sep 2020 Discontinued - Phase-II for Breast cancer (PO) (Bristol-Myers Squibb pipeline, September 2020) (ASLAN Pharmaceuticals, September 2020)
  • 15 Sep 2020 Discontinued - Phase-II for Gastric cancer (Late-stage disease, Metastatic disease) in Australia (PO) (Bristol-Myers Squibb pipeline, September 2020) (ASLAN Pharmaceuticals, September 2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top